The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the ...

Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry. Kamala Harris Could Break 32-Year Record in Texas ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced ...